Advertisement

Momenta Pharmaceuticals Inc., a Cambridge-based developer of novel and generic drugs, has formed a $33 million collaboration deal with Baxter International Inc. that could balloon to more than $450 million with possible milestone payments included. The agreement centers around the development and commercialization of biosimilars, a form of generic drugs, in the areas of cancer, autoimmune disorders and chronic diseases.

SOURCE

Advertisement
Advertisement